Biogen Rare Disease Product Revenue
Rare Disease Product Revenue at Biogen came to $676.3M for the quarter to 30 Sep 2026, up 26.8% from a year earlier.
As Biogen reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 28 Oct 2026.
By quarter
| Period ending | Rare Disease Product Revenue | Change on a year | Filed |
|---|---|---|---|
| 30 Sep 2026 | $676.3M | up 26.8% | 28 Oct 2026 |
| 30 Jun 2026 | $601.7M | up 10.8% | 29 Jul 2026 |
| 31 Mar 2026 | $557.2M | down 1.1% | 29 Apr 2026 |
| 31 Dec 2025 | $514.6M | down 3.9% | 6 Feb 2026 |
| 30 Sep 2025 | $533.3M | up 7.8% | 30 Oct 2025 |
| 30 Jun 2025 | $543.0M | up 1.7% | 31 Jul 2025 |
| 31 Mar 2025 | $563.3M | up 32.9% | 1 May 2025 |
| 31 Dec 2024 | $535.3M | up 13.5% | 12 Feb 2025 |
| 30 Sep 2024 | $494.8M | up 10.0% | 30 Oct 2024 |
| 30 Jun 2024 | $534.1M | up 21.9% | 1 Aug 2024 |
| 31 Mar 2024 | $423.9M | down 4.4% | 24 Apr 2024 |
| 31 Dec 2023 | $471.8M | — | 14 Feb 2024 |
| 30 Sep 2023 | $449.9M | — | 8 Nov 2023 |
| 30 Jun 2023 | $438.0M | — | 25 Jul 2023 |
| 31 Mar 2023 | $443.3M | — | 25 Apr 2023 |
Definition
Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of Biogen: Product revenue, net revenue · MS Product Revenues · Revenue from anti-CD20 therapeutic programs revenue · SPINRAZA revenue · TYSABRI revenue · Royalty Attributed To OCREVUS revenue · Fumarate revenue · Specialized Immunology revenue · Interferon revenue · VUMERITY revenue · SYFOVRE revenue · SKYCLARYS revenue · Biosimilars revenue · AVONEX revenue · Contract manufacturing, royalty and other revenue · Contract manufacturing revenue · BENEPALI revenue · ZURZUVAE revenue · TECFIDERA revenue · Alzheimer's Collaboration revenue · PLEGRIDY revenue · EMPAVELI revenue · IMRALDI revenue · QALSODY revenue · financial statements
Every KPI and segment of BIIB, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.
